|
In the Dr. Perez interview on medscape today:
Medscape: How should clinicians approach patients with HER2-positive disease who have completed adjuvant therapy without trastuzumab?
Dr. Perez: This is something we are looking at. Based on the natural history of breast cancer, where we see the disease-free survival curves continue to decrease, this therapy is going to have to be considered for women who have completed chemotherapy. I don't think those women will derive as great a benefit as those who are treated with trastuzumab combined with chemotherapy, but it should be considered for these patients -- ideally, we should conduct a trial to quantitatively assess whether there is a meaningful benefit in this situation.
|